Acurx presents positive ibezapolstat microbiome data from its phase 2a trial at idweek

Staten island, n.y., oct. 4, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a scientific abstract and poster were presented on september 29 th at the infectious disease society of america (idsa) idweek™   2021 virtual conference entitled: "an open-label phase 2a study of ibezapolstat, a unique gram-positive selective spectrum (gpss™) antibiotic, for patients with clostridioides difficile infection.
ACXP Ratings Summary
ACXP Quant Ranking